Permira is considering a sale of Neuraxpharm in a deal that could value the pharmaceutical company at €3bn ($3.5bn) to €4bn, according to sources familiar with the matter cited by Bloomberg.

The private equity firm has begun discussions with potential advisers, and a formal sale process could launch before the end of the year. The talks remain at an early stage, and Permira could still choose to retain its stake.

Permira acquired Neuraxpharm in 2020 and has supported its expansion across Europe, Brazil, the Middle East, and Australia. The business, jointly headquartered in Spain and Germany, specialises in treatments for neurological and psychiatric disorders including epilepsy, Parkinson’s, Alzheimer’s, multiple sclerosis, depression, and psychosis. Its pipeline includes BRIUMVI, a multiple sclerosis therapy expected to provide a meaningful uplift to earnings.

With more than €80bn in committed capital across buyout, growth equity, and credit funds, Permira continues to be active globally. The firm employs over 500 people across 17 offices in Europe, the US, Asia, and the Middle East.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.